Jacques Dumas Net Worth

The estimated Net Worth of Jacques Dumas is at least $288 millier dollars as of 30 January 2018. Jacques Dumas owns over 8,750 units of Tetraphase Pharmaceuticals stock worth over $189,963 and over the last 8 years Jacques sold TTPH stock worth over $98,431.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jacques Dumas TTPH stock SEC Form 4 insiders trading

Jacques has made over 6 trades of the Tetraphase Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Jacques sold 7,497 units of TTPH stock worth $11,995 on 8 January 2019.

The largest trade Jacques's ever made was exercising 17,500 units of Tetraphase Pharmaceuticals stock on 22 August 2017 worth over $64,575. On average, Jacques trades about 5,682 units every 51 days since 2017. As of 30 January 2018 Jacques still owns at least 8,750 units of Tetraphase Pharmaceuticals stock.

You can see the complete history of Jacques Dumas stock trades at the bottom of the page.

What's Jacques Dumas's mailing address?

Jacques's mailing address filed with the SEC is C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Tetraphase Pharmaceuticals

Over the last 12 years, insiders at Tetraphase Pharmaceuticals have traded over $24,668,458 worth of Tetraphase Pharmaceuticals stock and bought 8,437,280 units worth $39,426,767 . The most active insiders traders include Capital, Llc Armistice Capi..., Llc Fmr et John Gordon Freund. On average, Tetraphase Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $2,306,253. The most recent stock trade was executed by Jolla Pharmaceutical Co La on 28 July 2020, trading 3,737,360 units of TTPH stock currently worth $7,474,720.

What does Tetraphase Pharmaceuticals do?

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Complete history of Jacques Dumas stock trades at Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals executives and stock owners

Tetraphase Pharmaceuticals executives and other stock owners filed with the SEC include:

• Patrick Taylor Horn,
  Chief Medical Officer
• Garen G Bohlin,
  Director
• Jeffrey Chodakewitz,
  Director
• David Charles Lubner,
  SVP and CFO
• Nancy Wysenski,
  Director
• Jacques Dumas,
  Chief ScientificOfficer
• Geraldine Henwood,
  Director
• L Patrick Gage,
  Director
• John Craig Thompson,
  Chief Operating Officer
• Jolla Pharmaceutical Co La,
  10% owner
• Larry Tsai,
  Chief Medical Officer
• Kamalam Unninayar,
  Chief Financial Officer
• Larry G. Edwards,
  See Remarks
• Guy Macdonald,
  Director
• Steven R. Ph.D. Gullans,
  Director
• Llc Fmr,
  10% owner
• L. Patrick Jr. Giroir,
  Director
• Joaquim Trias,
  10% owner
• Joyce A. Sutcliffe,
  Senior Vice President, Biology
• Venture Partners Ii Lp Medi...,
  
• Xiao Yi Xiao,
  10% owner
• Ventures Vi Lpcmea Ventures...,
  
• Venture Partners Qualified ...,
  
• Ventures Fund 2004 L P Flag...,
  
• Venture Partners Qualified ...,
  
• Ventures Vi Lpcmea Ventures...,
  
• Medical Fund Lp Blume Frede...,
  
• Douglas G. Cole,
  Director
• John Gordon Freund,
  Director
• Maria D Stahl,
  See Remarks
• Christopher Watt,
  Senior Vice President, Finance
• Capital, Llc Armistice Capi...,